Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

Research output: Contribution to journalArticlepeer-review

Authors

  • M H Cullen
  • C M Woodroffe
  • A D Chetiyawardana
  • N H Gower
  • R Joshi
  • R M Rudd
  • S G Spiro
  • J E Cook
  • C Trask
  • E Bessell
  • C K Connolly
  • J Tobias
  • R L Souhami

Abstract

Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

Details

Original languageEnglish
Pages (from-to)3188-94
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number10
Publication statusPublished - Oct 1999

Keywords

  • Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Ifosfamide, Lung Neoplasms, Male, Middle Aged, Mitomycin, Prognosis, Quality of Life, Survival Analysis